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Abstract: (1) Background: Obesity and type 2 diabetes have been suspected to impact both intrin-
sic metabolism and function of circulating immune cells. (2) Methods: To further investigate this
immunometabolic modulation, we profiled the phospholipidome of the peripheral blood mononu-
clear cells (PBMCs) in lean, normoglycemic obese (OBNG) and obese with dysglycemia (OBDysG)
individuals. (3) Results: The global PBMCs phospholipidome is significantly downmodulated in
OBDysG unlike OBNG patients when compared to lean ones. Multiple linear regression analyses
show a strong negative relationship between the global PBMCs phospholipidome and parameters
assessing insulin resistance. Even though all classes of phospholipid are affected, the relative abun-
dance of each class is maintained with the exception of Lyso-PC/PC and Lyso-PE/PE ratios that are
downmodulated in PBMCs of OBDysG compared to OBNG individuals. Interestingly, the percentage
of saturated PC is positively associated with glycated hemoglobin (HbA1c). Moreover, a few lipid
species are significantly downmodulated in PBMCs of OBDysG compared to OBNG individuals,
making possible to distinguish the two phenotypes. (4) Conclusions: This lipidomic study highlights
for the first-time modulations of the PBMCs phospholipidome in obese patients with prediabetes
and type 2 diabetes. Such phospholipidome remodeling could disrupt the cell membranes and the
lipid mediator’s levels, driving an immune cell dysfunction.
Keywords: lipidomic; phospholipids; membrane lipids; metabolism; obesity; type 2 diabetes;
immunology
1. Introduction
Obesity is characterized by a chronic low-grade inflammation that is initiated in adi-
pose tissue (AT) and interferes with insulin signaling and ultimately contributes to type 2
diabetes (T2D) [1,2]. Beside the activation of immune cells contributing to this sustained
inflammation, obesity has also detrimental effects on immunity as evidenced by higher
rates of vaccine failure, complications from infection [3–6] and increased risk of cancer [7–9].
These negative effects include the disruption of lymphoid tissue integrity, alterations in
the development, phenotype and activity of leukocytes as well as an impairment of the
crosstalk between innate and adaptive immune responses [3].
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Moreover, it has recently emerged that systemic metabolic disorders associated with
obesity may in turn impact both intrinsic metabolism and function of circulating immune
cells. Indeed, the activation, growth, proliferation, engagement of effector functions, and
return to homeostasis of immune cells are intimately linked with dynamic changes in
cellular metabolism [10]. Therefore, a microenvironment enriched or depleted in some
metabolites can disrupt both intrinsic metabolism and activation of immune cells [11]. This
« immunometabolic » concept is very well illustrated in the case of peripheral Natural
Killer (NK) cells in obesity [12]. Authors demonstrated that increased levels of circulat-
ing free fatty acids (FFAs) in obesity induce triglycerides (TG) synthesis in peripheral
NK cells. TG accumulation in lipid droplets, in turn, leads to the glucose metabolism
paralysis associated with an impairment of the NK cells cytotoxicity and a loss of tumor
immunosurveillance [12].
As modifications in plasma FFAs and lipids levels, an increase in blood glucose con-
centration could have an impact on both intrinsic metabolism and functions of peripheral
blood mononuclear cells (PBMCs). It’s known that the rate of glucose utilization can be
modulated by its availability [13]. Thus, a hyperglycemic environment could exacerbate
the glucose metabolism and glycolysis-dependent functions in circulating immune cells.
For example, the upregulation of the pro-inflammatory glycolysis-dependent properties
of trained atherogenic macrophages was proposed to mediate the higher susceptibility of
diabetic patients to develop cardiovascular diseases [14].
Besides glycolysis, other metabolic pathways such as those involving lipids or amino
acids can also instruct the functions of immune cells [10]. For example, the TG synthesis
was recently shown to play a key role in the pro-inflammatory activation of ex vivo
macrophages [15]. What about the metabolism of glycerophospholipids and sphingolipids
in circulating immune cells of obese and T2D patients? The glycerophospholipids are the
building blocks of cellular membranes with the phosphatidylcholine (PC) reaching up to
55% of total lipids in mammalian cell membranes. Besides glycerophospholipids, another
structural lipid class is represented by sphingomyelin (SM). Some glycerophospholipids
like phosphatidylinositol (PI), phosphatidylserine (PS), lyso-phosphatidylcholine (LPC)
and lyso-phosphatidylethanolamine (LPE) as well as ceramides (Cer) also play key roles in
signal transduction pathways [16,17].
Interestingly, a remodeling of the lipidome in PBMCs involving an upregulation of
sphingolipids was recently reported in children who later progressed to type 1 diabetes or
seroconverted to at least one antibody compared with the autoantibody-negative control
children [18]. Lipidomic studies carried out on the plasma of obese patients have shown
modulations of some lipid species or classes that have been positively or negatively associ-
ated with body mass index (BMI) and/or insulin resistance and glucose intolerance [19].
Similar associations have been observed in prediabetes and T2D [20] where several indi-
vidual molecular species and lipid classes have been prospectively associated with a risk
of T2D [21]. However, very little is known about the modulation of the PBMCs lipidome in
these patients.
The main objective of this work was to investigate the impact of obesity with or
without dysglycemia on the phospholipidome of PBMCs. Lipidomic analyses focused
on glycerophospholipids (PC, PE, PI, PS, LPC, LPE, LPI, LPS), sphingomyelin (SM) and
ceramides (Cer) from PBMCs and plasma samples of lean, obese with normoglycemia
(OBNG) and obese with dysglycemia (OBDysG) individuals. This lipidomic study high-
lights for the first-time a disruption of the PBMCs phospholipidome in obese patients with
dysglycemia compared to normoglycemic lean or obese individuals.
2. Materials and Methods
2.1. Participants
We studied a total of 57 individuals (aged 20–63 years) undergoing bariatric surgery
or recruited on a voluntary basis. The study was performed in accordance with the eth-
ical principles set forth in the Declaration of Helsinki and received approval from the
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ethics Committee of the Liège University Hospital, and all patients provided written in-
formed consent (Ethical committee number: 2016/244). Inclusion criteria were based
on age (subjects aged 18 to 65), BMI, fasting glucose and glycated hemoglobin (HbA1c)
as described below. Subjects with inflammatory or malignant diseases were excluded.
Subjects with dementia, mental retardation, altered state of consciousness, not allowing to
give their consent were also excluded. Participants underwent measurements of anthro-
pometric parameters and blood pressure (BP) during a medical consultation the day of
PBMCs sampling. Body mass index (BMI, kg/m2) was calculated from height and weight
measurement. Blood pressure was measured using tensiometer. The degree of insulin
sensitivity was estimated using the Homeostatic model assessment of insulin resistance
(HOMA-IR; fasting plasma glucose [mg/dL] × fasting plasma insulin [mU/L]/405). All
biochemical parameters measurements (fasting plasma glucose, lipid/cholesterol, insulin
and HbA1c) were performed at Liège university hospital center (CHU Liège) according
to ISO 15,189 standards. HbA1c was measured by HPLC on Menarini type HA 8180.
The participants were categorized in three groups based on the BMI and glycemic status:
(i) lean with normoglycemia (LEAN; BMI < 25 kg/m2, fasting glucose < 100 mg/dL and
HbA1c < 5.7%; n = 14), (ii) obese with normoglycemia (OBNG, BMI ≥ 30 kg/m2, fasting
glucose < 100 mg/dL and HbA1c < 5.7%; n = 18) and (iii) obese with dysglycemia (OB-
DysG, BMI ≥ 30 kg/m2 and fasting glucose ≥ 100 mg/dL and/or HbA1c ≥ 5.7%; n = 25),
the latter including 18 with prediabetes and 8 with T2D (fasting glucose ≥ 126 mg/dl
and/or HbA1c ≥ 6.5%) as defined by the ADA criteria [22]. Of the 25 OBDysG patients, 18
were on glucose-lowering treatment (metformin) and 9 on lipid-lowering agent (statins).
No OBNG patient was on glucose-lowering treatment nor on lipid-lowering agent. The
participants characteristics are shown in Table 1 and Table S1.
Table 1. Anthropometric, clinical and biological characteristics of the participants.
Overall
p-Value Lean OBNG OBDysG
n (f/m) NA 14 (9/5) 18 (12/6) 25 (12/13)
Age (years) >0.001 33.9 ± 9.7 39.1 ± 8.9 47.9 ± 11.3 ***;†
Body Weight (kg) >0.001 65.5 ± 10.5 112.7 ± 22.1 *** 120.6 ± 25.4 ***
BMI (kg/m2) >0.001 22.1 ± 1.9 40.3 ± 4.4 *** 40.6 ± 6.6 ***
Waist (cm) >0.001 76.2 ± 8.1 121.0 ± 13.9 *** 124.5 ± 14.9 ***
Systolic BP (mmHg) 0.003 122.3 ± 9.2 129.8 ± 13.9 140.9 ± 17.3 **
Diastolic BP (mmHg) 0.024 74.0 ± 9.2 83.2 ± 10.4 87.6 ± 16.1 *
Fasting glucose (mg/dL) >0.001 84.6 ± 5.3 90.2 ± 5.4 112.0 ± 32.5 ***;†
Fasting insulin (mU/L) >0.001 7.1 ± 3.3 22.9 ± 10.7 *** 32.6 ± 22.2 ***
HOMA-IR >0.001 1.48 ± 0.68 5.14 ± 2.43 *** 9.67 ± 8.79 ***
HbA1c (%) >0.001 5.27 ± 0.23 5.37 ± 0.20 6.20 ± 1.00 ***;†††
Type 2 diabetes NA 0/14 0/18 8/25
Triglycerides (g/L) >0.001 0.81 ± 0.35 1.49 ± 0.50 ** 1.87 ± 1.77 ***
Total cholesterol (g/L) 0.570 1.94 ± 0.31 2.05 ± 0.30 2.05 ± 0.41
HDL cholesterol (g/L) >0.001 0.76 ± 0.16 0.49 ± 0.10 *** 0.45 ± 0.10 ***
LDL cholesterol (g/L) 0.015 1.02 ± 0.31 1.29 ± 0.30 * 1.29 ± 0.35 *
C-reactive protein (mg/L) 0.001 2.12 ± 2.09 6.17 ± 5.88 * 7.33 ± 6.05 ***
Data are mean ± SD. Kruskal–Wallis followed by Dunn post hoc test was performed on data. Normoglycemic
obese (OBNG) or obese with dysglycemia (OBDysG) vs. Lean * p≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. OBDysG vs.
OBNG † p≤ 0.05; †† p ≤ 0.01; ††† p ≤ 0.001.
2.2. Sample Preparation
Fasting blood samples were collected in EDTA tubes and centrifuged to collect plasma.
Plasma was directly frozen (−80 ◦C). PBMCs were isolated from the remaining blood using
Ficoll-Paque™ PREMIUM (VWR) and immediately frozen at −80 ◦C.
2.3. Lipid Extraction
1 × 106 of PBMCs were sonicated for 10 s in 800 µL water and 100 µL of plasma
was diluted with water to reach 800 µL. Then 700 µL of these homogenized samples were
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then mixed with 800 µL 1N HCl:CH3OH 1:8 (v/v), 900 µL CHCl3 and 200 µg/mL of the
antioxidant 2,6-di-tert-butyl-4-methylphenol (BHT; Sigma Aldrich). The organic fraction
was evaporated using a Savant Speedvac spd111v (Thermo Fisher Scientific, Waltham,
MA, USA) at room temperature and the remaining lipid pellet was stored at −20 ◦C
under argon.
2.4. Mass Spectrometry
Just before mass spectrometry analysis, lipid pellets were reconstituted in running
solution (CH3OH:CHCl3:NH4OH; 90:10:1.25; v/v/v). Phospholipid (PL) species were
analyzed by electrospray ionization tandem mass spectrometry (ESI-MS/MS) on a hybrid
triple quadrupole/linear ion trap mass spectrometer (4000 QTRAP system; Applied Biosys-
tems SCIEX) equipped with a TriVersa NanoMate (Advion Biosciences) robotic nanosource
for automated sample injection and spraying. PL profiling was executed by (positive or
negative) precursor ion or neutral loss scanning at a collision energy of 50 eV/45 eV, 35 eV,
−35 eV, and −60 eV for precursor 184 (sphingomyelin (SM)/phosphatidylcholine (PC)),
neutral loss 141 (phosphatidylethanolamine (PE)), neutral loss 87 (phosphatidylserine
(PS)) and precursor 241 (phosphatidylinositol (PI)), respectively. PL quantification was
performed by multiple reactions monitoring (MRM), the transitions being based on the
neutral losses or the typical product ions as described above. Lipid standards PC25:0,
PC43:6, SM30:1, PE25:0, PE43:6, PI25:0, PI31:1, PI43:6, PS25:0, PS31:1, PS37:4, CER35:1,
Lyso PC13:0, Lyso PC17:1, Lyso PE13:0, Lyso PE17:1, Lyso PS13:0, Lyso PS17:1, Lyso PI13:0,
Lyso PI17:1 (Avanti Polar Lipids) were added based on the amount of DNA in the original
sample. Typically, a 3 min period of signal averaging was used for each spectrum. The
data were corrected for isotope effects as described by [23].
2.5. Lipidomic Statistical Analysis
All analyses were performed using R (version 4.0.5). Individual lipid species were
analyzed using principal component analysis with the “prcomp” function. Sums of lipid
abundances for each lipid class were calculated and compared across groups (see Table S2).
Normality was checked using (i) Shapiro–Wilk test, (ii) histogram, (iii) QQ-plot. If normality
was not respected for at least one of these three tests, normality was rejected. Variance
homogeneity was then checked with Levene test. If p < 0.05 for Levene test, normality was
rejected. Statistical comparisons for biological parameters and lipids abundance (absolute,
relative, sums of lipid abundances and ratio) were performed using Kruskal–Wallis non-
parametric analysis of variance (ANOVA), followed by Dunn multiple comparison tests
due to the abnormal distribution of continuous variables. All data are Mean ± SD and
statistical significance was considered when p ≤ 0.05.
The effect of different factors such as age, gender, biological variables and their
interactions on the lipidome was evaluated. Values were log-transformed prior to linear
regression statistical analysis. Associations between biological variables of patient and
lipid species were evaluated using linear models (“lm” function), before and after adjusting
for the other covariates (age or other biological variables). All p-values were adjusted for
multiple comparisons using the Benjamini-Hochberg (false discovery rate) method with the
“p.adjust” function. Relationships were considered significant when the adjusted-p-value
was ≤ 0.05.
Heatmaps and histograms were created using GraphPad Prism 7. For all analyses,
*** p ≤ 0.001; ** p ≤ 0.01; * p ≤ 0.05.
3. Results
3.1. Anthropometric, Clinical and Biological Characteristics of the Study Population
Anthropometric, clinical and biological characteristics of the study population are
summarized in Table 1. Similar to the BMI, the body weight and waist circumference
of both OBNG and OBDysG patients are significantly higher than in lean patients. Both
obesity phenotypes are characterized by a significant increase in their fasting insulin
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and HOMA-IR compared to lean patients. However, OBNG and OBDysG patients are
distinguished from each other by their fasting glucose and mainly by HbA1c. Indeed, these
two metabolic variables are significantly increased in OBDysG patients relative to both
OBNG and lean individuals. Both OBNG and OBDysG patients show higher triglyceride
and LDL cholesterol levels and lower HDL cholesterol concentrations relative to the lean
patients. The pro-inflammatory marker, C-reactive protein (CRP), is also increased in both
obesity phenotypes compared to lean individuals. Systolic and diastolic blood pressure
(BP), are significantly increased in OBDysG patients relative to lean patients.
Platelet and leukocyte compositions of patients’ blood are summarized in Table S1.
Amounts of blood leukocytes are significantly increased in both groups of obese patients
compared to lean patients. Relative values of different leukocyte types do not change
depending on obesity. Nevertheless, their absolute amount can vary depending on the
group. It is the case for neutrophils and eosinophils which are increased for OBDysG
compared to lean patients. Lymphocytes are increased in OBNG patients compared to
lean patients.
3.2. The Global PBMCs Phospholipidome Is Inversely Associated with Insulin Resistance in Obesity
Lipidomic analyses were performed on plasma and PBMCs from 14 lean individuals,
18 OBNG and, respectively, 24 or 25 OBDysG patients. The global phospholipidome (PC,
PE, PS, PI, LPC, LPE, LPS, LPI and SM) as well as ceramides were investigated. A total of
232 and 224 lipid species were detected in PBMCs and plasma, respectively.
As shown in Figure 1A, principal component analysis (PCA) analysis performed on
plasma lipidomic data enables to distinguish obese patients from lean individuals while
the two obesity phenotypes overlap. Interestingly, the phospholipidome of PBMCs allows
to cluster OBDysG and lean patients into two distinct sets with only a small overlap while
OBNG individuals are scattered among the other 2 subgroups (Figure 1B).
Then, we have compared the normalized absolute levels (nmol/mL for plasma and
nmol/mg DNA for PBMCs) for all detected lipid species in plasma or in PBMCs between
each patient’s category. The plasma phospholipidome undergoes important changes in
obese versus lean patients; 75 and 54 out of a total of 224 lipid species are significantly up- or
down-regulated in lean patients compared to OBDysG and OBNG, respectively (Figure 1C).
However, the overall profile is similar in both obese phenotypes; only one lipid species
(PI 36:4) is significantly differentially regulated between both obese groups (Figure 1C).
On the other hand, unlike OBNG individuals, the global PBMCs phospholipidome from
OBDysG patients is significantly downmodulated compared to lean patients (Figure 1D,
Table S2); 163 out of a total of 232 lipid species are significantly reduced in OBDysG
compared to lean patients against only 10 when OBNG and lean individuals are compared.
The whole plasma lipidome, unlike that of PBMCs, has already been the subject of
much work in the context of obesity and prediabetes/T2D. Therefore, we decided not to
further investigate the plasma phospholipidome and to focus on the modulation of PBMCs
phospholipidome in the rest of this work.
The down-modulation of the PBMCs phospholipidome in OBDysG patients affects all
classes of phospholipids. The PC, PE, LPC, LPE and SM classes are the most impacted; almost
all species of PC (50 out of 55, i.e., 91%, Figure 2A), PE (30 out of 42, i.e., 71%, Figure 2B),
LPC (13 out of 19, i.e., 68%, Figure 2C), LPE (13 out of 13, i.e., 100%, Figure 2C) and SM (16
out of 21, i.e., 76%, Figure S1A) are significantly down-regulated in OBDysG compared to
lean individuals. In the case of PE and PI, the down-modulation targets mostly the species
carrying more than 2 or 3 double bonds, respectively (Figure 2B, Figure S1B). A few PS species
are also affected without showing a clear pattern with respect to the acyl chain composition
(Figure S1B) while less than half of LPI and LPS species are affected (Figure S1C). In contrast,
ceramides seem to respond differently than phospholipids; indeed, some species are down-
modulated only in OBDysG patients while others decrease significantly in both types of obese
patients (Figure S1D).
Nutrients 2021, 13, 3461 6 of 17
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*** p ≤ 0.001. Kruskal-Wallis followed by Dunn post hoc test was performed on data. 
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significant difference when OBNG are compared to lean individuals (Figure 3). Neverthe-
less, regarding LPE and LPI classes, a significant downregulation is observed in OBDysG 
compared to OBNG patients. Despite this general decrease in the absolute abundance of 
each lipid class, the relative proportions of each lipid class are preserved, except for the 
LPE where relative abundance is significantly reduced in OBDysG compared to lean pa-
tients (2.2% vs. 3.8%, * p ≤ 0.05) (Table S3). 
Figure 2. Log2FC of all (A) PC, (B) PE and (C) Lyso-PC/-PE lipid species detected in PB Cs between lean and OBNG or
OBDysG patients and between the two obesity phenotypes (OBNG vs. OBDysG). Mean comparison * p≤ 0.05; ** p ≤ 0.01;
*** p ≤ 0.001. Kruskal-Wallis followed by Dunn post hoc test was performed on data.
Except for both LPS and LPI classes, the absolute abundance of each lipid class
is significantly downregulated in OBDysG in comparison to lean patients while there
is no significant difference when OBNG are compared to lean individuals (Figure 3).
Nevertheless, regarding LPE and LPI classes, a significant downregulation is observed
in OBDysG compared to OBNG patients. Despite this general decrease in the absolute
abundance of each lipid class, the relative proportions of each lipid class are preserved,
except for the LPE where relative abundance is significantly reduced in OBDysG compared
to lean patients (2.2% vs. 3.8%, * p ≤ 0.05) (Table S3).
We wanted to determine whether the changes in the phospholipidome were associ-
ated with differences in anthropometric, metabolic and inflammatory parameters. Many
plasma lipid species are known to be associated with age, gender and clinical lipids (total
cholesterol, HDL-cholesterol and triglyceride) [24]. What about PBMCs phospholipids?
In univariable analyses, gender, HDL, LDL and triglycerides are not associated with any
PBMCs lipid species or class. However, several phospholipid classes (PC, PE, SM and LPE)
are inversely associated with age (Table 2). A similar trend is observed for the Cer, LPC
and PI (Table 2). This negative association with age is particularly important for the LPEs.
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Almost all individual LPEs’ lipids (11 out of 13) are associated with age, justifying the
significant decrease in the relative abundance of this lipid class in OBDysG patients which
present higher mean age compared to the two other subgroups. In univariate analyses, the
main phospholipids classes are also negatively associated with BMI, CRP, HOMA-IR, fast-
ing insulin and HbA1c (Tables S4–S7 and S9). The relationships with BMI and HbA1c are
lost after adjustment for age (Table S4 and S9) while they are maintained in the case of CRP
(Table S5). Interestingly, strong negative associations between the PC, PE, PI, Cer and SM
are observed with both parameters allowing to assess insulin resistance, namely HOMA-IR
and fasting insulin. Moreover, these relationships are retained after correcting for age in
multivariate analyses (Tables S6 and S7). Any association with fasting glucose is observed
(Table S8). Altogether, these multiple linear regression analyses demonstrate that the global
PBMCs phospholipidome in obesity is not associated with dysglycemia estimated by fast-
ing glucose and HbA1c but rather with insulin resistance as demonstrated by a strong
negative association with HOMA-IR and especially with fasting insulin. Accordingly, we
analyzed the associations of all individual lipid species from each class with fasting insulin
after age adjustment. The β-coefficients and 95% confidence intervals are converted to
percentage change for interpretation of results (Figure 4). The lipid species which are the
most influenced by fasting insulin levels (negative correlation; p < 0.05 or <0.01) are PC (39
out of 55 species) and PE (23 out of 42 species) (Figure 4). Interestingly, the PC and PE lipid
species with less than 40 carbon atoms are most strongly associated with insulin (p < 0.01).
The levels of some of these PC and PE species decrease by more than 40% as the insulin
concentration increases by 1 mU/L (Figure 4). Moreover, no lipid species are positively
associated with fasting insulin (Figure 4).
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Table 2. Univariable associations between selected lipid species or classes and age. 
Figure 3. l t ance (n ol/ , s atients. ata
are ean ± 0.05; ** p 0.01; * p ≤ .001. Kruskal–Wallis followed by Dunn post hoc test as erf
Lean (n = 14), B (n = 18) and B ys (n = 25).
3.3. A Few Individual Phospholipidic Species Allow to Distinguish Obese Patients with
Dysglycemia from Normoglycemic Obese Individuals
Sixteen li id species belo ging to the PC (28:0), SM (d18:1/22:0, d18:1/20:1), LPC
(20:0, 20:3), LPE (18:1, 20:1, 16:0, 18:2, 20:2, 20:3, 22:3, 20:4) and LPI classes (18:0, 20:4) are
significantly downmodulated in OBDysG compared to OBNG patients, making possible to
distinguish the 2 obese phenotypes (Figure 5).
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Table 2. Univariable associations between selected lipid species or classes and age.
Age
Lipid class Unadjusted β (95% CI) p R2 (p-value)
PC −0.411 (−0.70, −0.13) 0.051 0.111 (0.007)
PE −0.386 (−0.67, −0.10) 0.051 0.097 (0.010)
PI −0.350 (−0.64, −0.06) 0.059 0.078 (0.020)
PS −0.246 (−0.64, 0.15) 0.291 0.008 (0.230)
SM −0.467 (−0.81, −0.12) 0.051 0.098 (0.010)
Cer −0.367 (−0.71, −0.03) 0.081 0.058 (0.040)
LPC −0.534 (−0.97, −0.09) 0.059 0.077 (0.021)
LPE −1.238 (−2.00, −0.47) 0.046 0.139 (0.002)
LPI −0.320 (−0.78, 0.14) 0.238 0.015 (0.177)
LPS −0.168 (−0.69, 0.36) 0.581 −0.011 (0.531)
Lipid species Unadjusted β (95% CI) p R2 (p-value)
PC 28:0 −0.445 (0.11, −1.00) 0.183 0.028 (0.122)
SM d18:1/20:1 −0.445 (−0.86, −0.03) 0.082 0.056 (0.042)
SM d18:1/22:0 −0.548 (−1.00, −0.09) 0.059 0.075 (0.022)
LPC 20:0 −0.623 (−0.05, −1.19) 0.076 0.060 (0.036)
LPC 20:3 −0.410 (0.05, −0.87) 0.135 0.036 (0.084)
LPE 16:0 −0.913 (−0.38, −1.45) 0.046 0.155 (0.001)
LPE 18:1 −1.098 (−0.45, −1.74) 0.046 0.154 (0.002)
LPE 20:1 −1.201 (−0.44, −1.96) 0.046 0.133 (0.003)
LPE 18:2 −1.199 (−0.49, −1.91) 0.046 0.150 (0.002)
LPE 20:2 −1.013 (−0.25, −1.77) 0.052 0.094 (0.011)
LPE 20:3 −1.192 (−0.43, −1.96) 0.046 0.129 (0.004)
LPE 22:3 −1.329 (−0.45, −2.21) 0.046 0.125 (0.005)
LPE 20:4 −1.445 (−0.45, −2.44) 0.051 0.111 (0.006)
LPE 22:4 −1.625 (−0.55, −2.71) 0.046 0.121 (0.005)
LPI 18:0 −0.264 (0.18, −0.71) 0.309 0.006 (0.252)
LPI 20:4 −0.385 (0.09, −0.86) 0.178 0.027 (0.118)
Data presented as β-coefficients and corresponding 95% confidence intervals (CI). All lipids were log-transformed
to the base 10 prior to analyses and all p-values represent significance of associations after correcting for multiple
comparisons using the Benjamini-Hochberg method (bold values indicate p < 0.05 after correction).
Univariate and multivariate linear regression analyses were also performed with
these lipid species. As previously shown for the LPE class, the 8 LPE species differen-
tially modulated between OBDysG and OBNG patients are inversely associated with age
(Table 2). These species do not show any correlation with any patient characteristics after
age adjustment except the LPE 16:0 that remains inversely associated with HOMA-IR
and fasting insulin (Tables S4–S9). However, the other lipid species, namely the PC 28:0,
both LPC (20:0, 20:3), both SM (d18:1/20:1, d18:1/22:0) and both LPI (18:0, 20:4), are not
correlated with age (Table 2). In univariate linear regression analyses, all of these lipid
species, with the exception of the LPI 20:4, are negatively associated with insulin resistance
(HOMA-IR, fasting insulin) and, for the most part, also with BMI and CRP (Tables S4–S7).
In addition, LPC 20:0 and both SM (d18:1/20:1, d18:1/22:0) are inversely associated with
HbA1c and the PC 28:0 is negatively correlated with both fasting glucose and HbA1c
(Tables S8 and S9).
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p < 0.05 and p < 0.01, respectively, after correction for multiple comparisons (Benjamini-Hochberg).
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change = (10ˆ β-coefficient−1) × 100) for interpretation of results.
3.4. The Relative Abundance of Saturated PC Is Increased and the Lyso-PC/PC Ratio Is Decreased
in PBMCs from OBDysG V rsus OBNG Patients
We also investigated whether the OBNG and/or OBDysG phenotypes are associ-
ated with changes in the composition of the PL acyl chains. The proportions of PL
classified according to their number of carbon atoms are not affected by obesity nor by
dysglycemia (Figure 6A). However, the percentage of PL with 0 unsaturation (i.e., satu-
rated) is significantly increased in OBDysG compared to OBNG while the frequency of
PL with 2 unsaturations is decreased in OBDysG versus lean patients (Figure 6B). This
up-regulation of the relative abundance of saturated PL is mainly due to the increase in the
percentage of saturated PC even if this signature is also visible for PE (Figure 6C). The PI
are not represented as no saturated PI was detected.




Figure 5. Individual lipid species downmodulated in PBMCs from OBDysG compared to OBNG patients. Data are mean 

































































































































































































































































































































































































































Figure 5. Individual lipid species downmodulated in PBMCs from OBDysG compared to OBNG patients. Data are mean
± SD. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Kruskal–Wallis followed by Dunn post hoc test was performed on data.




Figure 6. The percentage of saturated PC is increased in PBMCs from OBDysG compared to OBNG patients. Relative 
abundance of the PL species (PC + PE + PI + PS) comprised of (A) the same number of carbons or (B) the same number of 
unsaturation in their hydrocarbon chain and (C) relative abundance of saturated PC, PE or PS. Data are mean ± SD. Krus-
kall–Wallis test, Dunn’s multiple comparison test, * p < 0.05; ** p < 0.01. (D) Correlation between HbA1c (%) and percentage 
of saturated PC. n  =  54, r = Spearman’s rank correlation coefficient. 
The percentage of saturated PE is only positively associated with age (unadjusted β 
= 0.359; 95% CI (0.13, 0.59); p = 0.046). However, the percentage of saturated PC is not 
correlated neither with age, BMI, CRP nor with HOMA-IR and fasting insulin but shows 
a positive association with HbA1c (Figure 6D). 
Figure 6. The percentage of saturated PC is increased in PBMCs from OBDysG compared to OBNG patients. Relative
abundance of the PL species (PC + PE + PI + PS) comprised of (A) the same number of carbons or (B) the same number
of unsaturation in their hydrocarbon chain and (C) relative abundance of saturat d PC, PE or PS. Data are mean ± SD.
Kruskall–Wallis est, Dunn’s multiple comparison test, * p < 0.05; ** p < 0.01. (D) orrelation be ween HbA1c (%) and
percentage of saturated PC. n = 54, r = Spearman’s rank correlation coefficient.
The percentage of saturated PE is only positively associated with age (unadjusted
β = 0.359; 95% CI (0.13, 0.59); p = 0.046). However, the percentage of saturated PC is not
correlated neither with age, BMI, CRP nor with HOMA-IR and fasting insulin but shows a
positive association with HbA1c (Figure 6D).
Because previous studies suggest that altering the LPC/PC ratio of cell membranes
is sufficient to disrupt the physical properties of membranes [25], we also focused on the
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Lyso-PL/PL ratios. Interestingly, the LPC/PC ratio is significantly decreased in OBDysG
individuals when compared to OBNG patients (Figure 7). A significant decrease in the
LPE/PE ratio is also observed in OBDysG compared to OBNG individuals although the
inter-individual variability in each patient category is important (Figure 7). While the ratio
LPE/PE is only negatively associated with age, the LPC/PC ratio is not influenced by any
of the previously studied clinical variables.
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from OBDysG compared to lean patients which is mainly associated with insulin resistance
(i.e., HOMA-IR and fasting insulin). The main PL classes constituting the lipid bilayer of
ammalian cell membranes, namely the PC, SM and PE, are strongly downmodulated
suggesting a shrinkage of the membrane network. Their relative abundance seems to be
preserved, notably the PE/PC ratio (data not shown) playing a key role in cell membrane
homeostasis [26,27]. However, we observed that the LPC/PC ratio is significantly de-
creased in PBMCs from OBDysG compared to OBNG patients. Interestingly, this LPC/PC
ratio has just been proposed as a factor capable of modulating the physical properties
of cell membranes and the activity of membrane receptors. Indeed, a lipidomic analysis
recently performed on primary myocytes from individuals that are insulin-sensitive and
lean or insulin-resistant with obesity (OB) also revealed a global phospholipidome down-
modulation in OB myotubes [25]. Authors underlined the specific decrease in the LPC/PC
ratio in these OB myotubes that resulted from a greater expression of lysophosphatidyl-
choline acyltransferase 3 (LPCAT3), an enzyme involved in phospholipid transacylation
(Lands cycle). This disruption of the LPC/PC ratio induced a disorganization of membrane
phospholipids that was able to suppress insulin receptor phosphorylation [25].
Furthermore, we observed an increased percentage of saturated PC in the membranes
of PBMCs from OBDysG compared to OBNG patients. An upregulation of the phospholipid
acyl-chain saturation index is well-known to impair the membrane fluidity [26,28]. A
decreased membrane fluidity has been already described in red blood cells and leucocytes
in patients with T2D [29]. Such lipid bilayer stress can influence the activity of integral
proteins. In this context, we previously demonstrated that incorporation of saturated fatty
acids into PC induces a disruption of the plasma membrane Na/K-ATPase followed by K+
efflux and NLRP3 inflammasome-mediated IL-1β secretion in human macrophages [28].
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A few lipid species are significantly down-modulated in the PBMCs of OBDysG
compared to OBNG individuals allowing us to discriminate these two categories of patient;
this is the case for the PC 28:0, the LPC 20:0 and both SM d18:1/20:1 and d18:1/22:0.
Moreover, these species are inversely correlated to obesity (BMI), insulin resistance (HOMA-
IR, fasting insulin) and also dysglycemia (HbA1c). Thus, these PBMCs lipid species could
be potential novel predictors of glucose intolerance in obesity.
Altogether, these data suggest a shrinkage of the membrane network and membrane
physico-chemical alterations. Thus, such phospholipidome remodeling could disrupt
the function of circulating immune cells. Indeed, immune cells need to expand their
ER and Golgi membranes when they have to synthesize and secrete large amounts of
immunoglobulin or cytokines. T lymphocytes and monocytes are activated in response to
the stimulation of membrane receptors like T-cell receptor (TCR) or Toll-like receptor (TLR),
respectively; both kinds of receptors have been reported to be disturbed by changes in the
biophysical properties of membranes [26,30]. These data raise many questions. We do not
know if all cell membranes are impacted in PBMCs, membranes of organelles such as ER
and Golgi and/or the plasma membrane and whether all cell subpopulations, lymphocytes
and/or monocytes, are affected. Further lipidomic analyses performed on various cellular
fractions and on the different PBMCs subpopulations will allow to answer these questions.
What could be the triggering events of such a phospholipidome remodeling? Given the
global phospholipidome decrease, we can suspect that the glycerophospholipid synthesis
pathways are downmodulated in the PBMCs of OBDysG patients. The SM are also globally
affected and related with PC and PE through the same biosynthetic pathway. Thus, we
can assume that the decrease in SM levels is due to a lack of precursors. Because the
Lyso-PL/PL ratios are also altered, the Lands cycle enzymes could also be differentially
modulated in the PBMCs of OBDysG patients, as suggested by Ferrara et al. [25]. An
increasingly defended hypothesis suggests that systemic metabolism disturbances in obese
patients with insulin resistance or glucose intolerance can impact the intrinsic metabolism
of PBMCs through altered fuel supplies [10,11]. Modulations of some lipid classes have
already been observed in circulating immune cells of obese patients; this is the case of TG
which accumulate in lipid droplets of NK cells during obesity causing complete ‘paralysis’
of their glucose metabolism and cytotoxic activity [12]. Interestingly, FFAs added to
the culture medium of healthy NK cells are able to recapitulate the activation of the TG
synthesis pathways and the NK cells ‘paralysis’ [12]. FFAs are released in the blood of
obese patients as a result of an exacerbated lipolysis in adipocytes due to insulin resistance.
Therefore, FFAs concentrations are higher in patients with prediabetes or T2D than in
normoglycemic obese [31]. Since we report that the majority of glycerophospholipids and
SM species of PBMCs are strongly negatively associated with insulin, we cannot exclude a
role of blood FFAs or a direct effect of insulin on intrinsic lipid metabolism of leukocytes
from OBDysG patients. Transcriptomic analyzes coupled with the investigation of the
whole lipidome on PBMCs from OBDysG, OBNG and lean patients as well as on healthy
PBMCs treated ex vivo with FFAs or insulin will make possible to answer these questions.
The molecular mechanisms underlying the increase in PC saturation in OBDysG
patients are still elusive. We show in this work a positive correlation between the per-
centage of saturated PC and HbA1c. A hyperglycemic environment could exacerbate the
glucose metabolism and its conversion into saturated fatty acids via de novo lipogenesis
in leucocytes. It would be interesting to check the association between the percentage of
saturated PC and HbA1c on a larger cohort comprising not only obese patients with and
without dysglycemia but also lean individuals with or without glycemia disorders.
Limitations
This study has some limitations. Indeed, this cohort of patients was initially recruited
to perform other analyzes on PBMCs. Hence, the study is not powered for lipidomic
analyses and our sample size may have been too small to detect significant correlations for
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some variables. Further lipidomic analyses should be performed on a larger cohort whose
subgroups are better age- and sex-matched.
The majority of OBDysG patients in our study (18 of 25) were on treatment with
metformin, unlike OBNG and lean patients. Metformin is the first-line drug for T2D
treatment. However, its plasma glucose level-lowering effects are still not fully understood.
Metformin would mediate its primary antidiabetic action by preventing hepatic glucose
production through inhibition of the mitochondrial respiratory chain complex 1 [32]. The
activation of AMP-activated protein kinase (AMPK) by metformin was reported to inhibit
lipid synthesis in hepatocytes and mitigate hepatic steatosis and insulin resistance in fatty
liver mouse models [33]. However, it is not known whether this mechanism is relevant
in humans. Until now, nobody reported an impact of metformin on the lipid metabolism
in PBMCs from treated patients. However, to rule out this hypothesis, we compared
the levels of each phospholipid species or class as well as the percentage of saturated
PC in the PBMCs of metformin-treated (n = 18) and -untreated (n = 7) OBDysG patients.
No difference could be observed in the PBMCs phospholipidome of these two groups of
patients (data not shown).
Of the 25 OBDysG patients, 9 were on lipid-lowering agent (statins) treatment. Again,
when we compared the levels of all PBMCs phospholipid species, we did not observe any
difference between OBDysG patients with or without statin treatment (data not shown).
5. Conclusions
Notwithstanding these limitations, we report for the first time a disruption of the
PBMCs phospholipidome in obese patients with dysglycemia compared to normoglycemic
lean or obese individuals. A global decrease in the PBMCs phospholipidome is observed
in OBDysG patients and is strongly associated with insulin resistance. Some individual
lipid species that are downregulated in OBDysG compared to OBNG individuals seem to
be further associated with dysglycemia and could be potential novel predictors of glucose
intolerance in obesity. Interestingly, an enrichment of saturated PC is observed in PBMCs
from OBDysG patients compared to OBNG and is positively associated with HbA1c. The
PBMCs phospholipidome remodeling in OBDysG patients involving both an increased sat-
urated PC percentage and a decreased LPC/PC ratio could disrupt membrane homeostasis
and immune cell function. Further lipidomic analyzes should be extended to all lipid
classes (including TG, glycosphingolipids) and performed on leukocyte subpopulations.
Using an integrative approach with functional, lipidomic and transcriptomic analyses
would make possible to elucidate the origins of lipidome remodeling and its consequences
on immune cells.
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10.3390/nu13103461/s1, Figure S1: Fold change (Log2FC) of all (A) SM, (B) PI/PS, (C) Lyso-PI/-PS
and (D) Cer lipid species detected in PBMCs from lean compared to OBNG or OBDysG patients
and from OBNG vs. OBDysG individuals. Table S1: Participants blood cells composition. Table
S2. Individual PBMCs lipid species. Table S3. Relative abundance of each lipid class. Table S4.
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adjustment for age. Table S5. Univariable and multivariable associations between lipid classes
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